1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Autoimmune Neurological Disorders Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Autoimmune Neurological Disorders Market, by Disease Type
8.1.1. Multiple Sclerosis
8.1.1.1. Market Revenue and Forecast
8.1.2. Neuromyelitis Optica Spectrum Disorder (NMOSD)
8.1.2.1. Market Revenue and Forecast
8.1.3. Myasthenia Gravis
8.1.3.1. Market Revenue and Forecast
8.1.4. Autoimmune Encephalitis
8.1.4.1. Market Revenue and Forecast
8.1.5. Guillain-Barre Syndrome (GBS)
8.1.5.1. Market Revenue and Forecast
8.1.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.1.6.1. Market Revenue and Forecast
8.1.7. Other Autoimmune Neurological Disorders
8.1.7.1. Market Revenue and Forecast
9.1. Autoimmune Neurological Disorders Market, by Drug Class
9.1.1. Immunomodulators
9.1.1.1. Market Revenue and Forecast
9.1.2. Immunosuppressants
9.1.2.1. Market Revenue and Forecast
9.1.3. Monoclonal Antibodies
9.1.3.1. Market Revenue and Forecast
9.1.4. Corticosteroids
9.1.4.1. Market Revenue and Forecast
9.1.5. Plasma Exchange (PLEX)
9.1.5.1. Market Revenue and Forecast
9.1.6. Intravenous Immunoglobulin (IVIG)
9.1.6.1. Market Revenue and Forecast
9.1.7. B-cell Depleting Therapies
9.1.7.1. Market Revenue and Forecast
9.1.8. Other Targeted Therapies
9.1.8.1. Market Revenue and Forecast
10.1. Autoimmune Neurological Disorders Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast
10.1.3. Intravenous (IV)
10.1.3.1. Market Revenue and Forecast
10.1.4. Subcutaneous
10.1.4.1. Market Revenue and Forecast
11.1. Autoimmune Neurological Disorders Market, by End-Use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Neurology Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Research & Academic Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Homecare Settings
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Disease Type
12.1.2. Market Revenue and Forecast, by Drug Class
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by End-Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Disease Type
12.1.5.2. Market Revenue and Forecast, by Drug Class
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by End-Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Disease Type
12.1.6.2. Market Revenue and Forecast, by Drug Class
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by End-Use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Disease Type
12.2.2. Market Revenue and Forecast, by Drug Class
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by End-Use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Disease Type
12.2.5.2. Market Revenue and Forecast, by Drug Class
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by End-Use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Disease Type
12.2.6.2. Market Revenue and Forecast, by Drug Class
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by End-Use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Disease Type
12.2.7.2. Market Revenue and Forecast, by Drug Class
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by End-Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Disease Type
12.2.8.2. Market Revenue and Forecast, by Drug Class
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by End-Use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Disease Type
12.3.2. Market Revenue and Forecast, by Drug Class
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by End-Use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Disease Type
12.3.5.2. Market Revenue and Forecast, by Drug Class
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by End-Use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Disease Type
12.3.6.2. Market Revenue and Forecast, by Drug Class
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by End-Use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Disease Type
12.3.7.2. Market Revenue and Forecast, by Drug Class
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by End-Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Disease Type
12.3.8.2. Market Revenue and Forecast, by Drug Class
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by End-Use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Disease Type
12.4.2. Market Revenue and Forecast, by Drug Class
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by End-Use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Disease Type
12.4.5.2. Market Revenue and Forecast, by Drug Class
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by End-Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Disease Type
12.4.6.2. Market Revenue and Forecast, by Drug Class
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by End-Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Disease Type
12.4.7.2. Market Revenue and Forecast, by Drug Class
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by End-Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Disease Type
12.4.8.2. Market Revenue and Forecast, by Drug Class
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by End-Use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Disease Type
12.5.2. Market Revenue and Forecast, by Drug Class
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by End-Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Disease Type
12.5.5.2. Market Revenue and Forecast, by Drug Class
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by End-Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Disease Type
12.5.6.2. Market Revenue and Forecast, by Drug Class
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by End-Use
13.1. Biogen Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. F. Hoffmann-La Roche Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi S.A.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly and Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck KGaA
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Teva Pharmaceutical Industries Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. AstraZeneca PLC
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bristol-Myers Squibb
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. ImmunoGen, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
